✦ LIBER ✦

Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response

✍ Scribed by E. Cariani; M. Capucci; M. Micheletti; F. Spalenza; I. Zanella; A. Albertini; G. Rossi

Publisher: Springer
Year: 2003
Tongue: English
Weight: 114 KB
Volume: 82
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-003-0660-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o

CNS blast crisis of chronic myelogenous

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

✍ Martin Bornhauser; Andreas Jenke; Jens Freiberg-Richter; Jörgen Radke; UlrichS. 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 80 KB